The present invention relates to the use of an anti-HER2 antibody-drug conjugate (ADC) in the preparation of a medicament for the treatment of urothelial carcinoma. The medicament of the present invention is safe and effective for patients with urothelial carcinoma, especially locally advanced or metastatic urothelial carcinoma, and can effectively prolong the survival of the patient.本發明涉及抗HER2抗體藥物偶聯物(ADC)在製備用於治療尿路上皮癌的藥物中的用途。本發明所述的藥物對於尿路上皮癌特別是局部晚期或轉移性尿路上皮癌患者安全有效，能有效延長患者生存期。
